Product Description
AAB-003 is a humanized version of the anti-Abeta mouse antibody 3D6 and a derivative of bapineuzumab (AAB-001). (Sourced from: https://www.alzforum.org/therapeutics/aab-003)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Pfizer
Company Location: Eastern America
Company Founding Year: 1849
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Alzheimer Disease
Recent News Events
Date |
Type |
Title |
|---|